A microfluidic chip and immunomodulator vesicles and preparation method and application thereof

The tumor acidity-responsive immunomodulator vesicles prepared by microfluidic chips in the aqueous phase have solved the problems of poor drug inactivation and dispersion in the prior art, and achieved efficient and stable vesicle preparation and tumor targeting effects.

CN115318166BActive Publication Date: 2024-11-19SHENZHEN PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211058986.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-31
Publication Date
2024-11-19
Estimated Expiration
2042-08-31

AI Technical Summary

Technical Problem

The prior art has problems in the preparation of tumor immunomodulatory agent nanocarriers that use organic solvents lead to drug inactivation, complex purification process, poor particle dispersion and stability, and lack the ability to actively target tumor tissues.

Method used

Using microfluidic chips to prepare tumor acidity-responsive immunomodulator vesicles of about 100 nanometers in the aqueous phase. Through the laminar and turbulent flow mixing technology of the microfluidic chip, the antibody or pH-responsive polymer is used to prepare the antibody or Cytokines are encapsulated in vesicles, avoiding the use of organic solvents.

Benefits of technology

It achieves efficient and non-destructive aqueous phase preparation of antibodies or cytokines, improves the dispersion and stability of vesicles, and has the ability to respond to tumor microenvironment, enhancing the targeting of drugs and attenuation and enhancing effects of attenuation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0003826054800000011
    Figure HDA0003826054800000011
  • Figure HDA0003826054800000012
    Figure HDA0003826054800000012
  • Figure HDA0003826054800000021
    Figure HDA0003826054800000021
Patent Text Reader

Abstract

The present invention discloses a microfluidic chip and an immunomodulator vesicle and a preparation method and application thereof. The microfluidic chip includes a microfluidic chip substrate and arranged thereon: a first injection port, a second injection port, a third injection port, three main flow channels, two branch forks, four branch sub-channels, a first confluence fork, a second confluence fork, a turbulent mixing channel and an outlet. The method for preparing immunomodulator vesicles of the present invention comprises: firstly, introducing a solution of an antibody and / or a cytokine immunomodulator into the microfluidic chip through the third injection port, secondly introducing a tumor-targeted pH-responsive polymer solution through the second injection port, and finally introducing a buffer solution through the first injection port; the above three solutions form a laminar flow of a mixed solution at the second confluence fork and the first confluence fork, and then mix in the turbulent mixing channel, and obtain vesicles at the outlet. The present invention solves the problem of water-phase non-destructive preparation of antibody or cytokine delivery platform and its off-target in vivo.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of microfluidic synthetic nanomedicines, and relates to a microfluidic chip and immunomodulator vesicles, and a preparation method and application thereof. Background Art

[0002] Tumor immunotherapy is a new type of anti-tumor treatment, which eliminates the escape of tumor cells from immune cells and activates the patient's body immunity for anti-tumor treatment through intravenous injection of immunomodulators, such as immune checkpoint antibodies (PD-1, PD-L1, CTLA-4, CD47 and other antibodies) or cytokines (IL-2, TNF-α, TGF-β, etc.). Although immunomodulators have achieved good therapeutic effects in clinical trials, there is still a low objective response rate (about 30%), as well as immune-related adverse events such as systemic immune overreaction and sepsis, which greatly limits the clinical application of immunomodulators. In addition, immunomodulators such as antibodies or cytokines are biological macromolecules with biological activity, which are prone to denaturation and inactivation in complex environments.

[0003] The use of nanocarriers to deliver anticancer drugs can not only improve the tissue distribution of drugs and increase intratumoral enrichment, thereby achieving toxicity reduction and efficacy enhancement, but also enable multi-drug, multi-target, and multi-modal combined therapy by co-delivering different drugs, which has broad application prospects in tumor immunotherapy research. According to domestic and foreign research reports, the delivery of antibodies or cytokines through carriers that respond to the tumor microenvironment can effectively reduce immune-related adverse reactions. However, immunomodulators such as antibodies or cytokines are biologically active macromolecular proteins that are prone to denaturation and inactivation in complex environments. The preparation process of these nanomedicines requires chemical modification of antibodies or cytokines, which are not ideal delivery carriers.

[0004] Patent document CN 114129738 A discloses a method for preparing a tumor microenvironment-responsive immunotherapy antibody composite material: (1) dissolving 2-methylimidazole in deionized water to obtain a 2-methylimidazole solution, adding the selected immunotherapy antibody and BSA to mix and set aside; (2) dissolving zinc acetate dihydrate in deionized water to obtain a zinc acetate dihydrate solution, set aside; (3) fully mixing the solution obtained in step (1) with the solution obtained in step (2), collecting the precipitate by solid-liquid separation, and obtaining. However, the defects of the antibody delivery material preparation method in the above-mentioned prior art are that organic solvents are used in the preparation process, the purification process is complicated, and may cause the inactivation of immunomodulators such as antibodies or cytokines, and the material particles prepared by the ordinary solution mixing method have poor dispersion, uniformity, and stability, and lack the ability to actively target tumor tissues.

[0005] Therefore, there is an urgent need to develop a method with mild synthetic conditions and no need for complex purification to construct tumor microenvironment-responsive carriers to encapsulate immunomodulators such as antibodies or cytokines, so as to accurately deliver immunomodulators to the tumor site and achieve toxicity reduction and efficacy enhancement. Summary of the invention

[0006] The purpose of the present invention is to provide a tumor acidity response immunomodulator vesicle encapsulating antibodies and / or cytokines, and a preparation method and application thereof.

[0007] The preparation method of the present invention can prepare tumor acidity responsive immunomodulator vesicles encapsulating antibodies or cytokines with uniform particle size of about 100 nanometers in an aqueous phase without using an organic solvent, thereby solving the problem of lossless aqueous phase preparation of antibody or cytokine delivery platforms and their off-target effects in vivo.

[0008] The present invention provides a microfluidic chip, which comprises a microfluidic chip substrate and the following components arranged thereon:

[0009] A first injection port, a second injection port, a third injection port, three main flow channels, two branching forks, four branching sub-channels, a first converging fork, a second converging fork, a turbulent mixing channel and a sample outlet;

[0010] The first injection port and the second injection port are respectively connected to one of the main flow channels, and each of the main flow channels is connected to two of the branching sub-channels through one of the branching forks and respectively merges into the first confluent fork and the second confluent fork;

[0011] The third injection port sequentially merges with the second confluence fork and the first confluence fork through the third main flow channel;

[0012] The first confluence fork is connected to the turbulent mixing channel through the extended third main flow channel, and the turbulent mixing channel is connected to the sample outlet.

[0013] In the present invention, the first injection port is used to introduce an alkaline phosphate buffer solution;

[0014] The second injection port is used to introduce an acidic aqueous solution of a tumor-targeting pH-responsive polymer;

[0015] The third injection port is used to introduce antibodies or cytokine immunomodulators;

[0016] One of the flow splitting forks is used to split the logistics entering a main channel from the first injection port into two flow splitting sub-channels connected thereto, and then merge at the first confluence fork to form a laminar flow; the other flow splitting fork is used to split the logistics entering another main channel from the second injection port into another two flow splitting sub-channels connected thereto, and merge at the second confluence fork to form a laminar flow after passing through the third main channel with the logistics introduced through the third injection port, and then flow into the first confluence fork through the extended third main channel to form a laminar flow;

[0017] a turbulent mixing channel, used for mixing the solutions flowing out of the two converging forks;

[0018] A sample outlet is used to export the tumor acidity response immunomodulator vesicles containing antibodies or cytokines obtained by mixing in the turbulent mixing channel.

[0019] In the above-mentioned microfluidic chip, the turbulent mixing channel is a double helix, specifically, after flowing out of the first confluence fork, it passes through a spiral channel with increasingly smaller pitches, and after reaching the center of the spiral, it is connected to the sample outlet through another parallel spiral channel with increasingly larger pitches.

[0020] In the above-mentioned microfluidic chip, the distances between the first injection port, the second injection port, the third injection port and the sample outlet are reduced accordingly;

[0021] The first injection port, the second injection port, the third injection port and the outlet port are located on the same straight line.

[0022] The present invention also provides a method for preparing tumor acidity responsive immunomodulator vesicles encapsulating antibodies and / or cytokines using the above-mentioned microfluidic chip, comprising the following steps:

[0023] First, a solution of an antibody and / or cytokine immunomodulator is introduced into the microfluidic chip through the third injection port via a syringe pump, and secondly, a tumor-targeted pH-responsive polymer solution is introduced into the microfluidic chip through the second injection port via a syringe pump, and finally, a flushing solution is introduced into the microfluidic chip through the first injection port via a syringe pump; the above three solutions form a laminar flow of a mixed solution at the second confluence fork and the first confluence fork, and then are mixed in the turbulent mixing channel, and tumor acidity-responsive immunomodulator vesicles encapsulating antibodies and / or cytokines are obtained at the outlet.

[0024] In the above method, the antibody includes at least one of PD-1, PD-L1, CTLA-1, CD47, SIRPα, LAG-3, TIM-3, TIGIT, VISTA, TNF-α, TGF-β, IFN-γ and IL-6;

[0025] The cytokine comprises at least one of IL-1β, IL-2, IL-8 and IL-17;

[0026] The tumor-targeting pH-responsive polymer comprises at least one of RGD polypeptide, folic acid and mannose as molecules used for tumor targeting;

[0027] The tumor-targeted pH-responsive polymer includes a compound containing a hexacyclic tertiary amine structure in the main chain and / or the side chain, and the compound containing a hexacyclic tertiary amine structure in the main chain and / or the side chain is preferably mannose-polymethyl methacrylate (betaine)-polymethyl methacrylate (hydroxyethylpiperidine); the compound containing a hexacyclic tertiary amine structure in the main chain and / or the side chain has pH ultrasensitivity, which is conducive to the formation of vesicles encapsulating antibodies or cytokines in the microfluidic chip through pH induction, and can also quickly respond to the acidic microenvironment of the tumor to release the loaded drug.

[0028] In the above method, in the mixed solution system:

[0029] The mass concentration ratio of the antibody and / or cytokine immunomodulator to the tumor-targeting pH-responsive polymer solution may be 1:0.1-200, and more preferably 2:1

[0030] The mass concentration of the antibody and / or cytokine immunomodulator may be 1 to 20 mg / mL, preferably 8 mg / mL;

[0031] The concentration of the tumor-targeting pH-responsive polymer solution may be 0.1 to 20 mg / mL, preferably 1 to 5 mg / mL, and more preferably 4 mg / mL;

[0032] The pH of the tumor-targeted pH-responsive polymer solution may be 1 to 6, preferably 3 to 5, and more preferably 4;

[0033] The concentration of the buffer solution introduced through the first injection port may be 0.1 to 20 mol / L, preferably 1 to 5 mol / L, and more preferably 1 mol / L;

[0034] The pH of the buffer solution introduced through the first injection port may be 8-14, preferably 9-12, and more preferably 10.

[0035] In the above method, at the first injection port, the flow rate of the buffer solution may be 10 to 200 mL / h, preferably 50 mL / h;

[0036] At the second injection port, the flow rate of the tumor-targeted pH-responsive polymer solution may be 1 to 20 mL / h, preferably 2 mL / h;

[0037] At the third injection port, the flow rate of the antibody or cytokine immunomodulator may be 0.01-2 mL / h, preferably 0.1 mL / h.

[0038] In a specific embodiment of the present invention, at the first injection port, the flow rate of the phosphate buffer solution may be 50 mL / h; at the second injection port, the flow rate of the pH responsive polymer solution may be 2 mL / h; at the third injection port, the flow rate of the antibody or cytokine immunomodulator may be 0.1 mL / h;

[0039] In the above method, the solvent of the solution of the antibody and / or cytokine immunomodulator is the buffer solution; the buffer system is selected from at least one of phosphoric acid, citric acid, carbonic acid, acetic acid, barbituric acid and Tris (tris(hydroxymethyl)aminomethane), preferably a phosphate buffer system;

[0040] The solvent of the tumor-targeting pH-responsive polymer solution is selected from a dilute solution of at least one of acetic acid, sulfuric acid and hydrochloric acid.

[0041] In the present invention, the preparation method specifically comprises the following steps:

[0042] The antibody and / or cytokine immunomodulator solution is introduced into the microfluidic chip through the third injection port via a syringe pump at a flow rate of 0.01 to 2 mL / h, the tumor-targeted pH-responsive polymer solution is introduced into the microfluidic chip through the second injection port via a syringe pump at a flow rate of 1 to 20 mL / h, and the phosphate buffer solution is introduced into the microfluidic chip through the first injection port via a syringe pump at a flow rate of 10 to 200 mL / h, forming a laminar flow at the second confluence fork and the first confluence fork, and then mixing in the turbulent mixing channel, and obtaining the tumor acidity-responsive immunomodulator vesicles encapsulating antibodies and / or cytokines at the outlet;

[0043] Among them, in the system after the above solutions are mixed, the mass concentration of the antibody and / or cytokine immunomodulator can be 1-20 mg / mL; the concentration of the tumor-targeted pH-responsive polymer solution can be 0.1-20 mg / mL, and the pH of the tumor-targeted pH-responsive polymer solution can be 1-6; the concentration of the phosphate buffer solution can be 0.1-20 mol / L, and the pH can be 8-14; and the ratio of the mass concentration of the antibody and / or cytokine immunomodulator to the mass concentration of the tumor-targeted pH-responsive polymer solution can be 1:0.1-200.

[0044] The present invention also provides the tumor acidity response immunomodulator vesicles encapsulating antibodies and / or cytokines prepared by the above method.

[0045] Preferably, the average particle size of the tumor acidity responsive immunomodulator vesicles may be 100 nanometers.

[0046] Preferably, the tumor acidity responsive immunomodulator vesicles present a vesicle structure.

[0047] The present invention further provides a drug, the active ingredient of which is the above-mentioned tumor acidity response immunomodulator vesicles encapsulating antibodies and / or cytokines.

[0048] The present invention has the following beneficial effects:

[0049] 1. The method of synthesizing nanomedicines using a microfluidic chip in the present invention has the advantages of high throughput, high repeatability, low energy consumption, etc., and the experimental parameters during synthesis are more controllable. The solutions introduced through each injection port flow into the confluence fork through the flow channel to form a laminar flow and are mixed in the turbulent channel. The mixing effect is better and it is easier to integrate the sensor unit and feedback control.

[0050] 2. The microfluidic chip synthesis method can continuously and rapidly produce vesicles containing immunomodulators, with high production efficiency and good dispersibility and stability of the vesicles. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 It is a two-dimensional planar schematic diagram of the microfluidic chip of the present invention.

[0052] Figure 2 The schematic diagram is a structural diagram of immunomodulator-loaded vesicles prepared by a microfluidic chip according to the present invention.

[0053] The marks in the figure are as follows:

[0054] 1, 2, 3 are the first injection port, the second injection port, and the third injection port respectively; 4 is the sample outlet; 5, 8 are the flow splitting forks respectively; 6, 7, 9, 10 are the flow splitting sub-channels; 11, 12 are the first confluence fork and the second flow fork respectively; 13 is the turbulent mixing channel;

[0055] 21 Targeting molecules: RGD peptide, folic acid or mannose; 22 Polyethylene glycol; 23 pH-responsive polymer vesicles; 24 Antibody 1; 25 Antibody 2.

[0056] Figure 3 This is a transmission electron micrograph of the immunomodulator-encapsulated vesicles of Example 1 of the present invention (×30k, accelerating voltage 100kV).

[0057] Figure 4 This is a dynamic light scattering particle size diagram of the immunomodulator-encapsulated vesicles of Example 1 of the present invention. DETAILED DESCRIPTION

[0058] To facilitate those skilled in the art to understand the technical solution, the present invention will be further described below in conjunction with the drawings in the embodiments, and the embodiments described are not intended to limit the present invention. All other embodiments obtained by those skilled in the art without creative work based on the present invention belong to the scope of protection of the present invention.

[0059] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0060] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0061] In the following examples, IL-2 and PD-L1 were purchased from Bio X Cell with product catalog numbers BE0043 and BE0101.

[0062] like Figure 1 As shown, the present invention provides a microfluidic chip, which includes a microfluidic chip substrate and arranged thereon:

[0063] A first sample inlet 1, a second sample inlet 2, a third sample inlet 3, three main flow channels (not marked in the figure), two branching forks 5, 8, four branching sub-channels 6, 7, 9, 10, a first converging fork 11, a second converging fork 12, a turbulent mixing channel 13 and a sample outlet 4;

[0064] The first injection port 1 is connected to a main flow channel, and is connected to two flow branch channels 6 and 7 through a flow branching fork 5 and converges to a first confluence fork 11; the second injection port 2 is connected to a main flow channel, and is connected to two flow branch channels 9 and 10 through a flow branching fork 8 and converges to a second confluence fork 12;

[0065] The third injection port 3 is connected to the second confluence fork 12 and the first confluence fork 11 in sequence through the third main flow channel;

[0066] The first confluence fork 11 is connected to the turbulent mixing channel 13 through an extended third main flow channel, and the turbulent mixing channel 13 is connected to the sample outlet 4 .

[0067] Preferably, the turbulent mixing channel 13 is double-helix shaped, specifically, after flowing out of the first confluence fork 11 , it passes through a spiral channel with a decreasing pitch, and after reaching the center of the spiral, it is connected to the sample outlet 4 through another parallel spiral channel with a decreasing pitch.

[0068] Preferably, the distances between the first injection port 1, the second injection port 2, the third injection port 3 and the sample outlet 4 decrease accordingly;

[0069] The first injection port 1 , the second injection port 2 , the third injection port 3 and the sample outlet 4 are located on the same straight line.

[0070] The method for preparing the tumor acidity response immunomodulator vesicles encapsulating antibodies and / or cytokines provided by the present invention specifically comprises the following steps:

[0071] The antibody and / or cytokine immunomodulator solution is introduced into the microfluidic chip through the third injection port via a syringe pump at a flow rate of 0.01 to 2 mL / h, the tumor-targeted pH-responsive polymer solution is introduced into the microfluidic chip through the second injection port via a syringe pump at a flow rate of 1 to 20 mL / h, and the phosphate buffer solution is introduced into the microfluidic chip through the first injection port via a syringe pump at a flow rate of 10 to 200 mL / h, a laminar flow is formed at the second confluence fork and the first confluence fork, and then mixed in the turbulent channel, and the tumor acidity-responsive immunomodulator vesicles encapsulating antibodies and / or cytokines are obtained at the outlet;

[0072] Among them, in the system after the above solutions are mixed, the mass concentration of the antibody and / or cytokine immunomodulator can be 1-20 mg / mL; the concentration of the tumor-targeted pH-responsive polymer solution can be 0.1-20 mg / mL, and the pH of the tumor-targeted pH-responsive polymer solution can be 1-6; the concentration of the phosphate buffer solution can be 0.1-20 mol / L, and the pH can be 8-14; and the ratio of the mass concentration of the antibody and / or cytokine immunomodulator to the mass concentration of the tumor-targeted pH-responsive polymer solution can be 1:0.1-200.

[0073] like Figure 2 , which is a schematic diagram of the structure of the immunomodulatory agent-encapsulated vesicles prepared by the microfluidic chip in the experiment of the present invention, and specifically can encapsulate antibodies or cytokines.

[0074] The present invention dissolves the tumor-targeted pH-responsive polymer in an acidic aqueous solution first, and mixes it with a weakly alkaline antibody or cytokine solution at the first confluence fork 11 to form a laminar flow. The polymer pH-responsive block near the center of the liquid flow is rapidly hydrophobicized, and after mixing with an alkaline phosphate buffer solution at the second confluence fork 12, the polymer pH-responsive block near the outside of the liquid flow is also rapidly hydrophobicized. The laminar mixed solution is fully mixed in the turbulent mixing channel 13, and the pH-responsive polymer forms a vesicle structure, wrapping the antibody or cytokine solution in the internal water cavity, and the average particle size of the vesicle is about 100 nanometers. Since the vesicles encapsulating antibodies or cytokines can respond to the acidic microenvironment of the tumor, the present invention is called a tumor acidity-responsive immunomodulator.

[0075] Example 1: Method for encapsulating IL-2 cytokine immunomodulator vesicles

[0076] A method for preparing immunomodulator vesicles encapsulating IL-2 cytokine, comprising the following steps:

[0077] a. dissolving a pH responsive material, including a pH sensitive polymer, in an acidic buffer solution;

[0078] b. Introduce the solution into the Figure 1 The microfluidic chip shown;

[0079] c. Adjust the pressure of the injection port to ensure that the liquid 1 (phosphate buffer solution with a pH of 10 and 1 mol / L) enters the splitter channels 6 and 7 at the splitter fork 5, and the liquid 2 (tumor-targeted pH-responsive polymer solution (mannose-polyethylene glycol-polymethyl methacrylate (hydroxyethyl piperidine), the solvent is a dilute hydrochloric acid solution (mass concentration 4 mg / mL, pH 4)) enters the splitter channels 9 and 10 at the splitter fork 8 at a uniform flow rate, and the fluid at the solution confluence forks 11 and 12 is in a laminar flow state;

[0080] d. The three solutions are turbulently mixed in the double-helix turbulent mixing channel 13 and discharged from the sample outlet 4.

[0081] In order to control the liquid to enter the flow channel in a laminar flow state and mix in a laminar flow at the solution confluence fork, the flow rate ratio of the first inlet 1, the second inlet 2, and the third inlet 3 is 50:2:0.1, the alkaline phosphate buffer is introduced through the first inlet 1 at a flow rate of 200, 150, 100 or 50 mL / h, the pH response material acidic aqueous solution is introduced from the second inlet 2 at a flow rate of 4, 3, 2 or 1 mL / h, and the antibody aqueous solution is introduced from the third inlet 3 at a flow rate of 0.4, 0.3, 0.2 or 0.1 mL / h.

[0082] The present invention uses a microfluidic chip to quickly prepare vesicles containing immunomodulators. The transmission electron microscopy image of the prepared vesicles containing immunomodulators is as follows: Figure 3 shown by Figure 3 It can be seen that it has uniform particle dispersion; the dynamic light scattering particle size diagram of the immunomodulator-encapsulated vesicles of the present invention is as follows Figure 4 As shown by Figure 4 From the data, we can see that its particle size is about 100 nanometers.

[0083] Example 2: Preparation of a tumor acidity response immunomodulator vesicle encapsulating PD-L1 antibody

[0084] A method for preparing a tumor acidity response immunomodulator vesicle encapsulating an antibody specifically comprises the following steps:

[0085] A solution of PD-L1 antibody (mass concentration 8 mg / mL) is introduced into the microfluidic chip through the third injection port 3 by a syringe pump at a flow rate of 0.1 mL / h, passes through the main flow channel and the branching fork 5 into the branching sub-channels 6 and 7, and converges at the first confluence fork 11 to form a laminar flow.

[0086] The tumor-targeted pH-responsive polymer solution (mannose-polyethylene glycol-polymethyl methacrylate (hydroxyethylpiperidine), the solvent is a dilute hydrochloric acid solution (mass concentration 4 mg / mL, pH 4) is introduced into the microfluidic chip through the second injection port 2 by a syringe pump at a flow rate of 2 mL / h, passes through the main flow channel and the diversion fork 8 into the diversion sub-channels 9 and 10, and converges at the second confluence fork 12 to form a laminar flow.

[0087] A phosphate buffer solution with a pH of 10 and 1 mol / L is introduced into the microfluidic chip through the first injection port 1 via a syringe pump at a flow rate of 50 mL / h, and converges in turn at the second confluence fork 12 and the first confluence fork 11 through the third mainstream channel to form a laminar flow.

[0088] The laminar flows of the three solutions are mixed in the turbulent mixing channel 13 , and the tumor acidity response immunomodulator vesicles encapsulating the antibody are obtained at the sample outlet 4 .

Claims

1. A method for preparing tumor acidity responsive immunomodulator vesicles encapsulating antibodies and / or cytokines using a microfluidic chip, comprising the following steps: First, a solution of an antibody and / or cytokine immunomodulator is introduced into the microfluidic chip through the third injection port via a syringe pump, and secondly, a tumor-targeted pH-responsive polymer solution is introduced into the microfluidic chip through the second injection port via a syringe pump, and finally, a buffer solution is introduced into the microfluidic chip through the first injection port via a syringe pump; the above three solutions form a laminar flow of a mixed solution at the second confluence fork and the first confluence fork, and then are mixed in the turbulent mixing channel, and tumor acidity-responsive immunomodulator vesicles encapsulating antibodies and / or cytokines are obtained at the outlet; The microfluidic chip comprises a substrate and: A first injection port, a second injection port, a third injection port, three main flow channels, two branching forks, four branching sub-channels, a first converging fork, a second converging fork, a turbulent mixing channel and a sample outlet; The first injection port and the second injection port are respectively connected to one of the main flow channels, and each of the main flow channels is connected to two of the branching sub-channels through one of the branching forks and respectively merges into the first confluent fork and the second confluent fork; The third injection port sequentially merges with the second confluence fork and the first confluence fork through the third main flow channel; The first confluence fork is connected to the turbulent mixing channel through the extended third mainstream channel, and the turbulent mixing channel is connected to the sample outlet; The turbulent mixing channel is in a double helical shape; The distances between the first injection port, the second injection port, the third injection port and the injection port and the sample outlet decrease accordingly; The first injection port is used to introduce an alkaline phosphate buffer solution; The second injection port is used to introduce an acidic aqueous solution of a tumor-targeted pH-responsive polymer; The third injection port is used to introduce antibodies or cytokine immunomodulators; The tumor-targeted pH-responsive polymer includes a compound having a six-membered tertiary amine structure in the main chain and / or the side chain, specifically including mannose-polymethyl methacrylate (betaine)-polymethyl methacrylate (hydroxyethylpiperidine); In the mixed solution system: The mass concentration ratio of the antibody and / or cytokine immunomodulator to the tumor-targeted pH-responsive polymer solution is 1:0.1-200.

2. The method according to claim 1, characterized in that The antibody comprises at least one of PD-1, PD-L1, CTLA-1, CD47, SIRPα, LAG-3, TIM-3, TIGIT, VISTA, TNF-α, TGF-β, IFN-γ and IL-6; The cytokine comprises at least one of IL-1β, IL-2, IL-8 and IL-17; The tumor-targeting pH-responsive polymer comprises at least one of RGD polypeptide, folic acid and mannose as the molecule used for tumor targeting.

3. The method according to claim 1 or 2, characterized in that: In the mixed solution system: The mass concentration of the antibody and / or cytokine immunomodulator is 1 to 20 mg / mL; The concentration of the tumor-targeting pH-responsive polymer solution is 0.1 to 20 mg / mL; The pH of the tumor-targeting pH-responsive polymer solution is 1 to 6; The concentration of the buffer solution introduced through the first injection port is 0.1 to 20 mol / L; The pH of the buffer solution introduced through the first injection port is 8-14.

4. The method according to claim 1 or 2, characterized in that: At the first injection port, the flow rate of the buffer solution is 10 to 200 mL / h; At the second injection port, the flow rate of the tumor-targeted pH-responsive polymer solution is 1 to 20 mL / h; At the third injection port, the flow rate of the antibody or cytokine immunomodulator is 0.01-2 mL / h.

5. The method according to claim 1 or 2, characterized in that: The solvent of the solution of the antibody and / or cytokine immunomodulator is the buffer solution; The buffer solution is selected from at least one of phosphoric acid, citric acid, carbonic acid, acetic acid, barbituric acid and Tris (tris(hydroxymethyl)aminomethane); The solvent of the tumor-targeting pH-responsive polymer solution is selected from a dilute solution of at least one of acetic acid, sulfuric acid and hydrochloric acid.

6. The tumor acidity responsive immunomodulator vesicles encapsulating antibodies and / or cytokines prepared by the method according to claim 1 or 2.

7. A drug, characterized in that The active ingredient of the drug is the tumor acidity response immunomodulator vesicles encapsulating antibodies and / or cytokines as described in claim 6.